TRIM-AGHD was found in this study to be highly responsive to patient-reported response to treatment in adults naïve to GH therapy.
The once-weekly novel growth hormone derivative was favored over once-daily hGH in this head-to-head trial that evaluated treatment satisfaction.
Growth hormone replacement therapy in adults is effective, but not risk-free. Find out what you know about the good vs not-so-good.
The novel long-acting recombinant human growth hormone may lower number of growth hormone treatments from daily to 2 times per month.
Pituitary dysfunction secondary to traumatic brain injury is receiving increased scrutiny and GHD is the most common isolated deficit. Which test to use?
A new orally administered diagnostic test for adult human growth hormone deficiency also may prove more convenient for patients and clinicians.